MedTrace Logo

A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants

NCT04388501 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2025-03-30

No results posted yet for this study

Summary

The purpose of this study is to evaluate the potential pharmacokinetics (PK) interaction between milvexian and atorvastatin (and its metabolites) in healthy participants at steady state.

Conditions

  • Healthy

Interventions

DRUG

Milvexian

Participants will receive milvexian capsules orally qd for 5 days as per the assigned treatment sequence.

DRUG

Atorvastatin

Participants will receive atorvastatin tablets orally qd for 5 days as per the assigned treatment sequence.

Sponsors & Collaborators

  • Janssen Pharmaceutica N.V., Belgium

    lead INDUSTRY

Principal Investigators

  • Janssen Pharmaceutica N.V., Belgium Clinical Trial · Janssen Pharmaceutica N.V., Belgium

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2021-10-25
Completion
2021-10-27

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04388501 on ClinicalTrials.gov